Business Description
Esperion Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US29664W1053
Description
Financial Strength
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.7 | |||||
Equity-to-Asset | -0.98 | |||||
Debt-to-Equity | -0.78 | |||||
Debt-to-EBITDA | -6.62 | |||||
Interest Coverage | 0.09 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | -4.85 | |||||
Beneish M-Score | 0.53 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -48.5 | |||||
3-Year EBITDA Growth Rate | 30.7 | |||||
3-Year EPS without NRI Growth Rate | 27.1 | |||||
3-Year FCF Growth Rate | 28.4 | |||||
3-Year Book Growth Rate | -1.2 | |||||
Future 3-5Y Total Revenue Growth Rate | 66.96 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 48.05 | |||||
9-Day RSI | 52.93 | |||||
14-Day RSI | 52.63 | |||||
6-1 Month Momentum % | -41.81 | |||||
12-1 Month Momentum % | 90.59 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.97 | |||||
Quick Ratio | 1.49 | |||||
Cash Ratio | 1.08 | |||||
Days Inventory | 462.89 | |||||
Days Sales Outstanding | 64.88 | |||||
Days Payable | 229.19 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -65.8 | |||||
Shareholder Yield % | -25.43 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 81.82 | |||||
Operating Margin % | 1.78 | |||||
Net Margin % | -35.46 | |||||
FCF Margin % | -3.57 | |||||
ROA % | -35.5 | |||||
ROIC % | 11.44 | |||||
ROC (Joel Greenblatt) % | -824.01 | |||||
ROCE % | -31.49 |
GF Value Rank
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Forward PE Ratio | 8.55 | |||||
PS Ratio | 1.13 | |||||
EV-to-EBIT | -11.27 | |||||
EV-to-Forward-EBIT | 1.45 | |||||
EV-to-EBITDA | -11.28 | |||||
EV-to-Forward-EBITDA | 1.45 | |||||
EV-to-Revenue | 1.65 | |||||
EV-to-Forward-Revenue | 0.69 | |||||
EV-to-FCF | -46.28 | |||||
Earnings Yield (Greenblatt) % | -8.87 | |||||
FCF Yield % | -2.62 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Esperion Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 277.788 | ||
EPS (TTM) ($) | -0.86 | ||
Beta | 1.67 | ||
Volatility % | 154.02 | ||
14-Day RSI | 52.63 | ||
14-Day ATR ($) | 0.114643 | ||
20-Day SMA ($) | 1.800515 | ||
12-1 Month Momentum % | 90.59 | ||
52-Week Range ($) | 0.71 - 3.365 | ||
Shares Outstanding (Mil) | 196.22 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 5 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Esperion Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Esperion Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Esperion Therapeutics Inc Frequently Asked Questions
What is Esperion Therapeutics Inc(LTS:0IIM)'s stock price today?
When is next earnings date of Esperion Therapeutics Inc(LTS:0IIM)?
Does Esperion Therapeutics Inc(LTS:0IIM) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |